Max Schreuer

1.0k total citations
20 papers, 727 citations indexed

About

Max Schreuer is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Max Schreuer has authored 20 papers receiving a total of 727 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Molecular Biology and 9 papers in Immunology. Recurrent topics in Max Schreuer's work include Cancer Immunotherapy and Biomarkers (11 papers), Melanoma and MAPK Pathways (10 papers) and CAR-T cell therapy research (7 papers). Max Schreuer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Melanoma and MAPK Pathways (10 papers) and CAR-T cell therapy research (7 papers). Max Schreuer collaborates with scholars based in Belgium, United States and Netherlands. Max Schreuer's co-authors include Bart Neyns, Yanina Jansen, Inès Chevolet, Teofila Seremet, Jeroen de Filette, Brigitte Velkeniers, Bert Bravenboer, Hendrik Everaert, Vibeke Krüse and Reinhart Speeckaert and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and The Lancet Oncology.

In The Last Decade

Max Schreuer

18 papers receiving 719 citations

Peers

Countries citing papers authored by Max Schreuer

Since Specialization

Citations

This map shows the geographic impact of Max Schreuer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Schreuer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Schreuer more than expected).

Fields of papers citing papers by Max Schreuer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Schreuer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Schreuer. The network helps show where Max Schreuer may publish in the future.

Co-authorship network of co-authors of Max Schreuer

This figure shows the co-authorship network connecting the top 25 collaborators of Max Schreuer. A scholar is included among the top collaborators of Max Schreuer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Schreuer. Max Schreuer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Severe treatment-induced inflammatory polyarthritis in advanced melanoma patients: 2 case reports 2022 ·Melanoma Research ·(unknown), Max Schreuer, (unknown), (unknown), Bart Neyns, Sandrine Aspeslagh	0
2	The ION-Ghent guidelines for the management of immune related adverse events (irAE's) 2017 ·Ghent University Academic Bibliography (Ghent University) ·Vibeke Krüse, Max Schreuer, Karim Vermaelen, Piet Ost, Tessa Kerre, Barbara De Moerloose, Liève Brochez	1
3	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial 2017 ·The Lancet Oncology ·Max Schreuer, Yanina Jansen, Simon Planken, Inès Chevolet, Teofila Seremet, Vibeke Krüse, Bart Neyns	114
4	Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy 2017 ·Melanoma Research ·Teofila Seremet, (unknown), Max Schreuer, Yanina Jansen, (unknown), Hakim El Housni, Danielle Líénard, V. del Mármol, Pierre Heimann, Bart Neyns	15
5	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients 2016 ·Journal of Translational Medicine ·Teofila Seremet, Alexander Koch, Yanina Jansen, Max Schreuer, Sofie Wilgenhof, V. del Mármol, Danielle Líénard, Kris Thielemans, (unknown), Mark Kockx, Wim Van Criekinge, Pierre G. Coulie, Tim De Meyer, Nicolas van Baren, Bart Neyns	24
6	Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO) 2016 ·Annals of Oncology ·Yanina Jansen, Elisa A. Rozeman, (unknown), Marnix Geukes Foppen, Max Schreuer, Johannes V. van Thienen, Lars Bastholt, Henrik Schmidt, John B.A.G. Haanen, Inge Marie Svane, Ana Arance, Christian U. Blank, Bart Neyns	4
7	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors 2016 ·Journal of Translational Medicine ·Max Schreuer, Geert Meersseman, (unknown), Yanina Jansen, Inès Chevolet, (unknown), Sofie Wilgenhof, Teofila Seremet, Bart Jacobs, Ronald Buyl, Geert Maertens, Bart Neyns	116
8	COMBI-rechallenge: a phase II clinical trial on dabrafenib plus trametinib in BRAFV600-mutant melanoma patients who previously experienced progression on BRAF(+MEK)-inhibition 2016 ·Annals of Oncology ·Max Schreuer, Vibeke Krüse, Yanina Jansen, Bart Neyns	1
9	Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab 2016 ·The Journal of Clinical Endocrinology & Metabolism ·Jeroen de Filette, Yanina Jansen, Max Schreuer, Hendrik Everaert, Brigitte Velkeniers, Bart Neyns, Bert Bravenboer	172
10	Single-center "real life experience" with pembrolizumab (PEMBRO) in pretreated advanced melanoma patients. 2016 ·Journal of Clinical Oncology ·Yanina Jansen, Max Schreuer, Bart Neyns	4
11	Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma 2015 ·Journal of Translational Medicine ·Inès Chevolet, Reinhart Speeckaert, Max Schreuer, Bart Neyns, Olga Krysko, Claus Bachert, Mireille Van Gele, Nanja van Geel, Liève Brochez	52
12	Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma 2015 ·Melanoma Research ·Teofila Seremet, Danielle Líénard, Mariano Suppa, Anne‐Laure Trépant, Sandrine Rorive, (unknown), (unknown), Yanina Jansen, Max Schreuer, V. del Mármol, Bart Neyns	10
13	Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma 2015 ·OncoImmunology ·Inès Chevolet, Reinhart Speeckaert, Max Schreuer, Bart Neyns, Olga Krysko, Claus Bachert, Benjamin Hennart, Delphine Allorge, Nanja van Geel, Mireille Van Gele, Liève Brochez	92
14	Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib 2015 ·Melanoma Research ·Yanina Jansen, Peter Janssens, Anne Hoorens, Max Schreuer, Teofila Seremet, Sofie Wilgenhof, Bart Neyns	33
15	Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients 2015 ·Melanoma Research ·Inès Chevolet, Max Schreuer, Reinhart Speeckaert, Bart Neyns, Isabelle Hoorens, Nanja van Geel, Vibeke Krüse, Benjamin Hennart, Delphine Allorge, Mireille Van Gele, Liève Brochez	10
16	Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma 2015 ·Melanoma Research ·Max Schreuer, Geert Meersseman, (unknown), Yanina Jansen, Teofila Seremet, (unknown), Inès Chevolet, Sofie Wilgenhof, Geert Maertens, Bart Neyns	14
17	Quantitative assessment of BRAF V600 mutant cell-free tumor DNA from plasma as a diagnostic and therapeutic biomarker in pts with BRAF V600 mutant melanoma. 2015 ·Journal of Clinical Oncology ·Max Schreuer, Geert Meersseman, Yanina Jansen, Teofila Seremet, Inès Chevolet, (unknown), Sofie Wilgenhof, Geert Maertens, Bart Neyns	1
18	3328 A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases 2015 ·European Journal of Cancer ·Yanina Jansen, Jurgen Corthals, Sofie Wilgenhof, Max Schreuer, Carlo Heirman, K Thielemans, Bart Neyns	3
19	Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure 2014 ·Melanoma Research ·Max Schreuer, Inès Chevolet, Yanina Jansen, Teofila Seremet, Sofie Wilgenhof, Danielle Líénard, V. del Mármol, Bart Neyns	7
20	Peritumoral indoleamine 2,3‐dioxygenase expression in melanoma: an early marker of resistance to immune control? 2014 ·British Journal of Dermatology ·Inès Chevolet, Reinhart Speeckaert, Marc Haspeslagh, Bart Neyns, Vibeke Krüse, Max Schreuer, Mireille Van Gele, Nanja van Geel, Liève Brochez	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact